Saturday, August 19, 2017 3:41:34 PM
On a fundamental basis, first, things have drastically improved most specifically in the health of the balance sheet and given revenues are most likely sustainable at 40 to 45 million in 2017 and growing revs for 2018 with the new technology products rolled out recently and the recurring revenue model recently introduced, the company can becone cash flow positive that much quicker.
The share price has declined substantially and the toxic debt does need to be addressed.
However, company has stated that the share price decline has not meant that the business fundamentally has suffered
In terms of getting revenue contracts and/or their current business partner/vendor/customer relationships.
If toxic debt shows signs of coming under control and being eventually eliminated or reduced drastically, share price will experience a solid upward correction to catch up with the fundamental improvements.
IMO
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM